BubR1 is frequently repressed in acute myeloid leukemia and its re-expression sensitizes cells to antimitotic therapy

Haematologica

Volumn 98, Issue 12, 2013, Pages 1886-1895

  Schnerch, Dominik ^a,b   Schmidts, Andrea ^a   Follo, Marie ^a   Udi, Josefina ^a   Felthaus, Julia ^a   Pfeifer, Dietmar ^a   Engelhardt, Monika ^a   Wäsch, Ralph ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPHASE PROMOTING COMPLEX; ANTIMITOTIC AGENT; BUB1 RELATED PROTEIN; BUB3 PROTEIN; CELL CYCLE PROTEIN 20; CYCLIN B; DOXYCYCLINE; F BOX PROTEIN; MESSENGER RNA; NOCODAZOLE; PROTEASOME; PROTEIN MAD2; SECURIN; UVOMORULIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; M PHASE CELL CYCLE CHECKPOINT; MICROARRAY ANALYSIS; MITOSIS INHIBITION; PROTEIN EXPRESSION; SISTER CHROMATID; UBIQUITINATION; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MITOSIS; MOLECULAR SEQUENCE DATA; NOCODAZOLE; PROTEIN-SERINE-THREONINE KINASES;

EID: 84884136594     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.087452     Document Type: Article

References (40)

1. Wagner HP, Swidzinska PM, Hirt A. Variable duration of vincristine-induced metaphase block in leukemic and nornal bone marrow cells of children. Med Pediatr Oncol. 1977;3(1):75-83.
2. Landini I, Bartolozzi B, Banchelli I, Degli Innocenti A, Nocentini O, Bernabei PA. In vitro activity of vinorelbine on human leukemia cells. J Chemother. 2001;13 (3):309-15.
3. Stanton RA, Gernert KM, Nettles JH, Aneja R. Drugs that target dynamic microtubules: a new molecular perspective. Med Res Rev. 2011;31(3):443-81.
4. Weaver BA, Cleveland DW. Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death. Cancer Cell. 2005;8(1):7-12.
5. Musacchio A, Salmon ED. The spindleassembly checkpoint in space and time. Nat Rev Mol Cell Biol. 2007;8(5):379-93.
6. Rieder CL, Maiato H. Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell. 2004;7(5):637-51.
7. Huang HC, Shi J, Orth JD, Mitchison TJ. Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly. Cancer Cell. 2009;16(4):347-58.
8. Gascoigne KE, Taylor SS. Cancer cells display profound intraand interline variation following prolonged exposure to antimitotic drugs. Cancer Cell. 2008;14(2):111-22.
9. Harley ME, Allan LA, Sanderson HS, Clarke PR. Phosphorylation of Mcl-1 by CDK1cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest. EMBO J. 2010;29(14):2407-20.
10. Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson DJ, et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature. 2011;471 (7336):110-4.
11. Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, Maser RS, et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature. 2011;471(7336):104-9.
12. Brito DA, Rieder CL. Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. Curr Biol. 2006;16(12):1194-200.
13. Schnerch D, Follo M, Krohs J, Felthaus J, Engelhardt M, Wäsch R. Monitoring APC/C activity in the presence of chromosomal misalignment in unperturbed cell populations. Cell Cycle. 2012;11(2):310-21.
14. Suijkerbuijk SJ, van Osch MH, Bos FL, Hanks S, Rahman N, Kops GJ. Molecular causes for BUBR1 dysfunction in the human cancer predisposition syndrome mosaic variegated aneuploidy. Cancer Res. 2010;70 (12):4891-900.
15. Shin HJ, Baek KH, Jeon AH, Park MT, Lee SJ, Kang CM, et al. Dual roles of human BubR1, a mitotic checkpoint kinase, in the monitoring of chromosomal instability. Cancer Cell. 2003;4(6):483-97.
16. Bohers E, Sarafan-Vasseur N, Drouet A, Paresy M, Latouche JB, Flaman JM, et al. Gradual reduction of BUBR1 protein levels results in premature sister-chromatid separation then in aneuploidy. Hum Genet. 2008;124(5):473-8.
17. Rio Frio T, Lavoie J, Hamel N, Geyer FC, Kushner YB, Novak DJ, et al. Homozygous BUB1B mutation and susceptibility to gastrointestinal neoplasia. N Engl J Med. 2010;363(27):2628-37.
18. de Jonge HJ, Woolthuis CM, Vos AZ, Mulder A, van den Berg E, Kluin PM, et al. Gene expression profiling in the leukemic stem cell-enriched CD34(+) fraction identifies target genes that predict prognosis in normal karyotype AML. Leukemia. 2011;25(12):1825-33.
19. Haferlach T, Kohlmann A, Wieczorek L, Basso G, Kronnie GT, Bene MC, et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol. 2010;28(15):2529-37.
20. Sethi VS, Jackson DV Jr, White DR, Richards F 2nd, Stuart JJ, Muss HB, et al. Pharmacokinetics of vincristine sulfate in adult cancer patients. Cancer Res. 1981;41(9 Pt 1):3551-5.
21. Park HY, Jeon YK, Shin HJ, Kim IJ, Kang HC, Jeong SJ, et al. Differential promoter methylation may be a key molecular mechanism in regulating BubR1 expression in cancer cells. Exp Mol Med. 2007;39(2):195-204.
22. Choi E, Choe H, Min J, Choi JY, Kim J, Lee H. BubR1 acetylation at prometaphase is required for modulating APC/C activity and timing of mitosis. EMBO J. 2009;28(14): 2077-89.
23. Boyapati A, Yan M, Peterson LF, Biggs JR, Le Beau MM, Zhang DE. A leukemia fusion protein attenuates the spindle checkpoint and promotes aneuploidy. Blood. 2007;109 (9):3963-71.
24. Hayette S, Tigaud I, Vanier A, Martel S, Corbo L, Charrin C, et al. AF15q14, a novel partner gene fused to the MLL gene in an acute myeloid leukaemia with a t(11;15)(q23;q14). Oncogene. 2000;19(38): 4446-50.
25. Kiyomitsu T, Obuse C, Yanagida M. Human Blinkin/AF15q14 is required for chromosome alignment and the mitotic checkpoint through direct interaction with Bub1 and BubR1. Dev Cell. 2007;13(5):663-76.
26. Nolte-'t Hoen EN, Almeida CR, Cohen NR, Nedvetzki S, Yarwood H, Davis DM. Increased surveillance of cells in mitosis by human NK cells suggests a novel strategy for limiting tumor growth and viral replication. Blood. 2007;109(2):670-3.
27. Vitrat N, Cohen-Solal K, Pique C, Le Couedic JP, Norol F, Larsen AK, et al. Endomitosis of human megakaryocytes are due to abortive mitosis. Blood. 1998;91(10): 3711-23.
28. Sanchez-Aguilera A, Montalban C, de la Cueva P, Sanchez-Verde L, Morente MM, Garcia-Cosio M, et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood. 2006;108(2):662-8.
29. Staal FJ, de Ridder D, Szczepanski T, Schonewille T, van der Linden EC, van Wering ER, et al. Genome-wide expression analysis of paired diagnosis-relapse samples in ALL indicates involvement of pathways related to DNA replication, cell cycle and DNA repair, independent of immune phenotype. Leukemia. 2010;24(3):491-9.
30. Lin SF, Lin PM, Yang MC, Liu TC, Chang JG, Sue YC, et al. Expression of hBUB1 in acute myeloid leukemia. Leuk Lymphoma. 2002;43(2):385-91.
31. Owellen RJ, Root MA, Hains FO. Pharmacokinetics of vindesine and vincristine in humans. Cancer Res. 1977;37(8 Pt 1):2603-7.
32. Gebbia V, Puozzo C. Oral versus intravenous vinorelbine: clinical safety profile. Expert Opin Drug Saf. 2005;4(5):915-28.
33. Rizzo J, Riley C, von Hoff D, Kuhn J, Phillips J, Brown T. Analysis of anticancer drugs in biological fluids: determination of taxol with application to clinical pharmacokinetics. J Pharm Biomed Anal. 1990;8(2):159-64.
34. Tao W, South VJ, Zhang Y, Davide JP, Farrell L, Kohl NE, et al. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell. 2005;8(1):49-59.
35. Wolf F, Wandke C, Isenberg N, Geley S. Dose-dependent effects of stable cyclin B1 on progression through mitosis in human cells. EMBO J. 2006;25(12):2802-13.
36. Wäsch R, Cross FR. APC-dependent proteolysis of the mitotic cyclin Clb2 is essential for mitotic exit. Nature. 2002;418(6897):556-62.
37. Manchado E, Guillamot M, de Carcer G, Eguren M, Trickey M, Garcia-Higuera I, et al. Targeting mitotic exit leads to tumor regression in vivo: modulation by Cdk1, Mastl, and the PP2A/B55alpha,delta phosphatase. Cancer Cell. 2010;18(6):641-54.
38. Wäsch R. Targeting mitotic exit for cancer treatment. Expert Opin Ther Targets. 2011;15(7):785-8.
39. Greene LM, Campiani G, Lawler M, Williams DC, Zisterer DM. BubR1 is required for a sustained mitotic spindle checkpoint arrest in human cancer cells treated with tubulin-targeting pyrrolo-1,5-benzoxazepines. Mol Pharmacol. 2008;73 (2):419-30.
40. Matson DR, Stukenberg PT. Spindle poisons and cell fate: a tale of two pathways. Mol Interv. 2011;11(2):141-50.